China in Vitro Diagnostics Market, Size, Forecast 2022-2027, Industry Trends, Growth, Share, Impact of COVID-19, Company Analysis
Description
China in Vitro Diagnostics Market, Size, Forecast 2022-2027, Industry Trends, Growth, Share, Impact of COVID-19, Company Analysis
China In-vitro diagnostics (IVD) Market is central to the provision of healthcare globally and is estimated to be US$ 18.9 Billion in 2027. Besides, China is the largest clinical laboratory market in Asia and one of the world's fastest-growing medical realms. Remarkably, over the past years, the rate of Chinese economic growth has been impressive, setting lucrative growth in GDP per year. In addition, the Chinese IVD landscape has historically been controlled by large international providers, with few domestic instrumentation and assay suppliers. Further, looking for a change, the start-up company sees the evolution of diagnostic platforms and assays presenting rapid detection for a wide range of blood-based markers.
China In-Vitro Diagnostics Industry is expanding with double-digit CAGR of 16.9% during 2021-2027
The Chinese IVDs industry is growing for years and has a significant global research and production base. In China, there is a solid clinical demand for the continuous development of IVD enterprises. However, new diagnostic requirements are constantly emerging, requiring clinical laboratories to carry out further testing projects and IVD enterprises to devise new technologies and products. Further, with the improved living standards of the Chinese people and the aging speed of the Chinese population, the demand for family health management is increasing; this avenue will thus become an important growth point for in vitro diagnostics enterprises.
How Coronavirus Benefited China In-Vitro Diagnostics Market Growth Trends
COVID–19 has further accelerated the growth of In-vitro diagnostics industry in China. As China has maintained the zero COVID policy, so in order to achieve that large number of PCR testing and Rapid Antigen tests needs to be performed. Due to COVID variants like Alpha, Beta, Gamma Delta, Delta Plus, and recently Omnicorn, the PCR test and Rapid Antigen tests will keep on happening in huge numbers. According to the Renub Research, the China In-Vitro Diagnostics Market Size was US$ 7.4 Billion in 2021.
Molecular Diagnostics Segment Registers Strong Growth in the Chinese in Vitro Diagnostics Market
In our report, By Segments - China in Vitro Diagnostics Market has been categorized into clinical chemistry, Immunoassay, Molecular Diagnostic, Microbiology, Haematology, and Self-Monitoring of Blood Glucose (SMBG), Point of Care Testing (POCT), and Coagulation. In IVD, one of the most valuable advances has been in the form of molecular diagnostic tools. As per our analysis, the polymerase chain reaction is the most conventional forefront of molecular diagnostics.
Besides, the real-time PCR products simultaneously detect viruses, bacteria, fungi, and parasites, allowing molecular laboratories to lower costs and drive better outcomes in molecular diagnostics. Remarkably, molecular diagnostic tests are used to detect specific sequences in DNA or RNA (including single nucleotide polymorphism (SNP), deletions, rearrangements, insertions, and others) that may or may not be associated with any disease.
Key Players in the Chinese IVD Market
Major international IVD companies already have a substantial presence in the Chinese market and represent potential competitive barriers to prospective market entrants. The key players include Roche Diagnostics, Sysmex Corporation, Bio-Rad Laboratories Inc., Shanghai Kehua Bio-Engineering Co. Ltd., Abbott Laboratories, Danaher Corporation, and BioMerieux SA.
The companies enjoy significantly greater financial resources to afford costs associated with product certification, clinical trials, and agent representation. Additionally, these companies can make the acquisitions necessary to establish direct distribution and local manufacturing operations.
Renub Research report titled “China In–Vitro Diagnostics (IVD) Market, By Segment [Clinical Chemistry, Immunoassay, Molecular Diagnostic, Microbiology, Hematology, Self-Monitoring of Blood Glucose (SMBG), Point of Care Testing (POCT), Coagulation], Companies (Roche Diagnostics, Sysmex Corporation, Bio-Rad Laboratories Inc., Shanghai Kehua Bio-Engineering Co. Ltd., Abbott Laboratories, Danaher Corporation, and BioMerieux SA)” studies the China IVD Industry.
Segments - China in Vitro Diagnostics Market has been covered 8 viewpoints:
1. Clinical Chemistry Market
2. Immunoassay Market
3. Molecular Diagnostic Market
4. Microbiology Market
5. Hematology Market
6. Self-Monitoring of Blood Glucose (SMBG) Market
7. Point of Care Testing (POCT) Market
8. Coagulation Market
Key Players covered in the report which has been studied from 3 viewpoints:
• Overview
• Initiatives & Recent Developments
• Revenue
Company Analysis:
1. Roche Diagnostics
2. Sysmex Corporation
3. Bio-Rad Laboratories Inc.
4. Shanghai Kehua Bio-Engineering Co. Ltd.
5. Abbott Laboratories
6. Danaher Corporation
7. BioMerieux SA
China In-vitro diagnostics (IVD) Market is central to the provision of healthcare globally and is estimated to be US$ 18.9 Billion in 2027. Besides, China is the largest clinical laboratory market in Asia and one of the world's fastest-growing medical realms. Remarkably, over the past years, the rate of Chinese economic growth has been impressive, setting lucrative growth in GDP per year. In addition, the Chinese IVD landscape has historically been controlled by large international providers, with few domestic instrumentation and assay suppliers. Further, looking for a change, the start-up company sees the evolution of diagnostic platforms and assays presenting rapid detection for a wide range of blood-based markers.
China In-Vitro Diagnostics Industry is expanding with double-digit CAGR of 16.9% during 2021-2027
The Chinese IVDs industry is growing for years and has a significant global research and production base. In China, there is a solid clinical demand for the continuous development of IVD enterprises. However, new diagnostic requirements are constantly emerging, requiring clinical laboratories to carry out further testing projects and IVD enterprises to devise new technologies and products. Further, with the improved living standards of the Chinese people and the aging speed of the Chinese population, the demand for family health management is increasing; this avenue will thus become an important growth point for in vitro diagnostics enterprises.
How Coronavirus Benefited China In-Vitro Diagnostics Market Growth Trends
COVID–19 has further accelerated the growth of In-vitro diagnostics industry in China. As China has maintained the zero COVID policy, so in order to achieve that large number of PCR testing and Rapid Antigen tests needs to be performed. Due to COVID variants like Alpha, Beta, Gamma Delta, Delta Plus, and recently Omnicorn, the PCR test and Rapid Antigen tests will keep on happening in huge numbers. According to the Renub Research, the China In-Vitro Diagnostics Market Size was US$ 7.4 Billion in 2021.
Molecular Diagnostics Segment Registers Strong Growth in the Chinese in Vitro Diagnostics Market
In our report, By Segments - China in Vitro Diagnostics Market has been categorized into clinical chemistry, Immunoassay, Molecular Diagnostic, Microbiology, Haematology, and Self-Monitoring of Blood Glucose (SMBG), Point of Care Testing (POCT), and Coagulation. In IVD, one of the most valuable advances has been in the form of molecular diagnostic tools. As per our analysis, the polymerase chain reaction is the most conventional forefront of molecular diagnostics.
Besides, the real-time PCR products simultaneously detect viruses, bacteria, fungi, and parasites, allowing molecular laboratories to lower costs and drive better outcomes in molecular diagnostics. Remarkably, molecular diagnostic tests are used to detect specific sequences in DNA or RNA (including single nucleotide polymorphism (SNP), deletions, rearrangements, insertions, and others) that may or may not be associated with any disease.
Key Players in the Chinese IVD Market
Major international IVD companies already have a substantial presence in the Chinese market and represent potential competitive barriers to prospective market entrants. The key players include Roche Diagnostics, Sysmex Corporation, Bio-Rad Laboratories Inc., Shanghai Kehua Bio-Engineering Co. Ltd., Abbott Laboratories, Danaher Corporation, and BioMerieux SA.
The companies enjoy significantly greater financial resources to afford costs associated with product certification, clinical trials, and agent representation. Additionally, these companies can make the acquisitions necessary to establish direct distribution and local manufacturing operations.
Renub Research report titled “China In–Vitro Diagnostics (IVD) Market, By Segment [Clinical Chemistry, Immunoassay, Molecular Diagnostic, Microbiology, Hematology, Self-Monitoring of Blood Glucose (SMBG), Point of Care Testing (POCT), Coagulation], Companies (Roche Diagnostics, Sysmex Corporation, Bio-Rad Laboratories Inc., Shanghai Kehua Bio-Engineering Co. Ltd., Abbott Laboratories, Danaher Corporation, and BioMerieux SA)” studies the China IVD Industry.
Segments - China in Vitro Diagnostics Market has been covered 8 viewpoints:
1. Clinical Chemistry Market
2. Immunoassay Market
3. Molecular Diagnostic Market
4. Microbiology Market
5. Hematology Market
6. Self-Monitoring of Blood Glucose (SMBG) Market
7. Point of Care Testing (POCT) Market
8. Coagulation Market
Key Players covered in the report which has been studied from 3 viewpoints:
• Overview
• Initiatives & Recent Developments
• Revenue
Company Analysis:
1. Roche Diagnostics
2. Sysmex Corporation
3. Bio-Rad Laboratories Inc.
4. Shanghai Kehua Bio-Engineering Co. Ltd.
5. Abbott Laboratories
6. Danaher Corporation
7. BioMerieux SA
Table of Contents
155 Pages
- 1. Introduction
- 2. Research Methodology
- 3. Executive Summary
- 4. Market Dynamics
- 4.1 Growth Drivers
- 4.2 Challenges
- 5. China In-Vitro Diagnostics Market
- 6. Market Share -China in Vitro Diagnostics
- 6.1 By Segment
- 7. Segments - China in Vitro Diagnostics Market
- 7.1 Clinical Chemistry Market
- 7.2 Immunoassay Market
- 7.3 Molecular Diagnostic Market
- 7.4 Microbiology Market
- 7.5 Hematology Market
- 7.6 Self-Monitoring of Blood Glucose (SMBG) Market
- 7.7 Point of Care Testing (POCT) Market
- 7.8 Coagulation Market
- 8. Development Environment of Chinese IVD Industry
- 8.1 Healthcare Reforms
- 8.2 Improving Quality at Grass-Root Level
- 8.3 Embracing Technology
- 9. China: Health Insurance and Reimbursement Policies
- 9.1 Health Insurance System
- 9.1.1 Basic Medical Insurance
- 9.1.2 Insurance for Other Groups
- 9.1.3 Rural Medical Insurance
- 9.1.4 Private Health Insurance
- 9.2 Reimbursement Rules
- 9.2.1 Device Reimbursement
- 9.2.2 Reimbursement for In-Vitro Diagnostics (IVDs)
- 10. Registration of In Vitro Diagnostic Reagents in China
- 10.1 Registration and Filing
- 10.2 Filing Obligation for Clinical Trials
- 10.3 Clinical Trial Institutions
- 10.4 Elimination of IVD Loophole for Research
- 10.5 Change of Manufacturing Address
- 10.6 Change of Main Supplier of an Antigen or Antibody
- 10.7 Update on China In-Vitro Diagnostics Registration
- 10.7.1 IVD Product Registration in China
- 10.7.2 China IVD Type Testing Process
- 10.7.3 Clinical Trials for IVD Products in China
- 11. Medical Devices and Reagents Class Registration in China
- 11.1 Process of Medical Device Registration in China
- 11.2 Classification of In-vitro Diagnostic Reagents in China
- 11.2.1 Class III: Highest Risk
- 11.2.2 Class II: Medium Risk
- 11.2.3 Class I: Lower Risk
- 11.3 China In-Vitro Diagnostics Reagents
- 11.3.1 Blood Screening Reagents — Drug Administration
- 11.3.2 Varieties of Blood Screening Reagents
- 11.3.3 Blood Screening Reagent Test
- 11.3.4 Nucleic Acid Detection Kits for Blood Screening
- 11.3.5 Radioactive Reagents — Drug Administration
- 11.3.6 Diagnostic Reagents - Medical Devices Management
- 12. Porters Five Forces
- 12.1 Overview
- 12.2 Bargaining Power of Buyers
- 12.3 Bargaining Power of Suppliers
- 12.4 Degree of Competition
- 12.5 Threat of New Entrants
- 12.6 Threat of Substitutes
- 13. Company Analysis
- 13.1 Roche Diagnostics
- 13.1.1 Overviews
- 13.1.2 Recent Developments
- 13.1.3 Revenues
- 13.2 Sysmex Corporation
- 13.2.1 Overviews
- 13.2.2 Recent Developments
- 13.2.3 Revenues
- 13.3 Bio-Rad Laboratories Inc.
- 13.3.1 Overviews
- 13.3.2 Recent Developments
- 13.3.3 Revenues
- 13.4 Shanghai Kehua Bio-Engineering Co. Ltd.
- 13.4.1 Overviews
- 13.4.2 Recent Developments
- 13.4.3 Revenues
- 13.5 Abbott Laboratories
- 13.5.1 Overviews
- 13.5.2 Recent Developments
- 13.5.3 Revenues
- 13.6 Danaher Corporation
- 13.6.1 Overviews
- 13.6.2 Recent Developments
- 13.6.3 Revenues
- 13.7 BioMerieux SA
- 13.7.1 Overviews
- 13.7.2 Recent Developments
- 13.7.3 Revenues
- 14. Profiles of Select Private Clinical Labs and Diagnostic Services Companies
- 14.1 Zhejiang Di’an Diagnostics Technology Co., Ltd.
- 14.1.1 Products and Services Offered by Di’an
- 14.2 ADICON Clinical Laboratories (Privately held)
- 14.2.1 Products and Services Offered by ADICON
- 14.3 Guangzhou Kingmed Diagnostics Center Co. Ltd.
- 14.3.1 Products and Services Offered by Kingmed
- 14.4 Kindstar Global (Privately held)
- 14.4.1 Products and Services Offered by Kindstar
- 14.5 BGI-Shenzhen
- 14.5.1 BGI’s Innovative Approach
- 14.6 OriGene Technologies
- 14.6.1 Products and Services Offered by OriGene
- List Of Figures:
- Figure-01: China In-Vitro Diagnostics Market (Million US$), 2016 – 2021
- Figure-02: Forecast for – China In-Vitro Diagnostics Market (Million US$), 2022 – 2027
- Figure-03: Segments – Clinical Chemistry Market (Million US$), 2016 – 2021
- Figure-04: Segments – Forecast for Clinical Chemistry Market (Million US$), 2022 – 2027
- Figure-05: Segments – Immunoassay Market (Million US$), 2016 – 2021
- Figure-06: Segments – Forecast for Immunoassay Market (Million US$), 2022 – 2027
- Figure-07: Segments – Molecular Diagnostic Market (Million US$), 2016 – 2021
- Figure-08: Segments – Forecast for Molecular Diagnostic Market (Million US$), 2022 – 2027
- Figure-09: Segments – Microbiology Market (Million US$), 2016 – 2021
- Figure-10: Segments – Forecast for Microbiology Market (Million US$), 2022 – 2027
- Figure-11: Segments – Hematology Market (Million US$), 2016 – 2021
- Figure-12: Segments – Forecast for Hematology Market (Million US$), 2022 – 2027
- Figure-13: Segments – Self-Monitoring of Blood Glucose (SMBG) Market (Million US$), 2016 – 2021
- Figure-14: Segments – Forecast for Self-Monitoring of Blood Glucose (SMBG) Market (Million US$), 2022 – 2027
- Figure-15: Segments – Point of Care Testing (POCT) Market (Million US$), 2016 – 2021
- Figure-16: Segments – Forecast for Point of Care Testing (POCT) Market (Million US$), 2022 – 2027
- Figure-17: Segments – Coagulation Market (Million US$), 2016 – 2021
- Figure-18: Segments – Forecast for Coagulation Market (Million US$), 2022 – 2027
- Figure-19: Roche Diagnostics – Global Revenue (Million US$), 2016 – 2021
- Figure-20: Roche Diagnostics – Forecast for Global Revenue (Million US$), 2022 – 2027
- Figure-21: Sysmex Corporation – Global Revenue (Million US$), 2016 – 2021
- Figure-22: Sysmex Corporation – Forecast for Global Revenue (Million US$), 2022 – 2027
- Figure-23: Bio-Rad Laboratories Inc. – Global Revenue (Million US$), 2016 – 2021
- Figure-24: Bio-Rad Laboratories Inc. – Forecast for Global Revenue (Million US$), 2022 – 2027
- Figure-25: Shanghai Kehua Bio-Engineering Co. Ltd. – Global Revenue (Million US$), 2016 – 2021
- Figure-26: Shanghai Kehua Bio-Engineering Co. Ltd. – Forecast for Global Revenue (Million US$), 2022 – 2027
- Figure-27: Abbott Laboratories – Global Revenue (Million US$), 2016 – 2021
- Figure-28: Abbott Laboratories – Forecast for Global Revenue (Million US$), 2022 – 2027
- Figure-29: Danaher Corporation – Global Revenue (Million US$), 2016 – 2021
- Figure-30: Danaher Corporation – Forecast for Global Revenue (Million US$), 2022 – 2027
- Figure-31: BioMerieux SA – Global Revenue (Million US$), 2016 – 2021
- Figure-32: BioMerieux SA – Forecast for Global Revenue (Million US$), 2022 – 2027
- List Of Tables:
- Table-01: China – In-Vitro Diagnostics Market Share by Segment (Percent), 2016 – 2021
- Table-02: China – Forecast for In-Vitro Diagnostics Market Share by Segment (Percent), 2022 – 2027
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
